Two placebo-controlled studies published in 2025 found that daily curcumin supplementation reduced liver fat, inflammation, and liver stiffness in patients with metabolic dysfunction-associated steatotic liver disease over a 12-month period.
By yourNEWS Media Newsroom
Two randomized, double-blind, placebo-controlled clinical trials published in 2025 found that curcumin supplementation significantly improved multiple liver health markers in adults diagnosed with metabolic dysfunction-associated steatotic liver disease, commonly known as fatty liver disease.
The studies, one published in the International Journal of Molecular Sciences and another in Nutrients, evaluated the effects of 1,500 milligrams of curcumin taken daily for one year. Researchers reported reductions in liver fat accumulation, liver stiffness, inflammatory activity, and oxidative stress among participants receiving curcumin compared to placebo groups.
The findings contribute to ongoing research into non-pharmaceutical approaches for managing fatty liver disease, a condition estimated by the World Health Organization to affect roughly 38% of adults worldwide. Investigators stated that both studies met rigorous clinical trial standards, including randomized assignment, placebo controls, and double-blinding procedures.
The larger of the two studies, published in September 2025 in the International Journal of Molecular Sciences, involved 227 obese adults with Type 2 diabetes and fatty liver disease. Participants were assigned either 1,500 milligrams of curcumin daily or a placebo over a 12-month period.
According to the study findings, individuals in the curcumin group experienced measurable declines in liver fat content and liver stiffness as assessed through transient elastography. Researchers also documented reductions in HbA1c levels, a long-term indicator of blood sugar regulation, along with decreases in inflammatory compounds including interleukin-1 beta and tumor necrosis factor-alpha.
The study further reported decreases in total body fat, waist circumference, and body mass index among participants taking curcumin. Investigators concluded that the turmeric-derived compound may provide supportive benefits for individuals managing both fatty liver disease and related metabolic disorders.
Researchers noted that previous studies examining curcumin’s metabolic effects suggested the compound may help preserve and support insulin-producing beta cells, which play a central role in glucose regulation.
A second study, published in June 2025 in Nutrients and conducted at Mahidol University in Bangkok, followed 78 patients diagnosed with metabolic liver disease using the same daily curcumin dosage for one year.
The Bangkok study produced findings similar to the larger trial. Researchers observed significant reductions in hepatic steatosis, the medical term for fat accumulation in the liver, along with lower liver stiffness measurements in participants receiving curcumin compared to placebo recipients.
The investigators also reported reductions in non-esterified fatty acids, which are associated with liver fat buildup and metabolic dysfunction. At the same time, antioxidant enzyme activity increased while markers of oxidative stress declined among patients taking curcumin.
Study authors concluded that curcumin demonstrated potential as a natural intervention for managing metabolic liver disease and reducing oxidative damage affecting liver tissue.
Fatty liver disease has emerged as one of the most widespread metabolic conditions globally. The disorder often progresses without symptoms during its early stages, and routine blood testing may fail to detect the condition until more advanced damage has occurred.
Medical researchers describe the disease as progressing through several stages, beginning with simple fat accumulation before advancing to inflammation, fibrosis, scarring, and in severe cases, cirrhosis or liver failure.
Currently, there are no approved pharmaceutical therapies specifically targeting early-stage fatty liver disease. Conventional medical recommendations generally focus on weight reduction, dietary improvement, and physical activity. Researchers noted that the lack of approved drug treatments has increased interest in nutritional and supplemental interventions that may support liver function.
The authors of both 2025 studies emphasized that bioavailability-enhanced curcumin formulations are important because standard curcumin is poorly absorbed by the body. The trials utilized forms designed to improve absorption, including combinations with compounds such as piperine or phospholipids.
Researchers also noted that improvements developed gradually over the course of several months rather than immediately, suggesting that sustained long-term use was necessary to achieve measurable effects.
While investigators described the findings as encouraging, they cautioned that additional large-scale and long-duration studies are still needed to fully evaluate long-term safety and effectiveness. They also stressed that curcumin supplementation should complement, rather than replace, dietary improvements, weight management, and exercise.
Source: Natural News
Original article
Comments